Deprez Pierre H, Moons Leon M G, OʼToole Dermot, Gincul Rodica, Seicean Andrada, Pimentel-Nunes Pedro, Fernández-Esparrach Gloria, Polkowski Marcin, Vieth Michael, Borbath Ivan, Moreels Tom G, Nieveen van Dijkum Els, Blay Jean-Yves, van Hooft Jeanin E
Department of Hepatogastroenterology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Divisie Interne Geneeskunde en Dermatologie, Maag-, Darm- en Leverziekten, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.
Endoscopy. 2022 Apr;54(4):412-429. doi: 10.1055/a-1751-5742. Epub 2022 Feb 18.
1: ESGE recommends endoscopic ultrasonography (EUS) as the best tool to characterize subepithelial lesion (SEL) features (size, location, originating layer, echogenicity, shape), but EUS alone is not able to distinguish among all types of SEL.Strong recommendation, moderate quality evidence. 2: ESGE suggests providing tissue diagnosis for all SELs with features suggestive of gastrointestinal stromal tumor (GIST) if they are of size > 20 mm, or have high risk stigmata, or require surgical resection or oncological treatment.Weak recommendation, very low quality evidence. 3: ESGE recommends EUS-guided fine-needle biopsy (EUS-FNB) or mucosal incision-assisted biopsy (MIAB) equally for tissue diagnosis of SELs ≥ 20 mm in size.Strong recommendation, moderate quality evidence. 4: ESGE recommends against surveillance of asymptomatic gastrointestinal (GI) tract leiomyomas, lipomas, heterotopic pancreas, granular cell tumors, schwannomas, and glomus tumors, if the diagnosis is clear.Strong recommendation, moderate quality evidence. 5: ESGE suggests surveillance of asymptomatic esophageal and gastric SELs without definite diagnosis, with esophagogastroduodenoscopy (EGD) at 3-6 months, and then at 2-3-year intervals for lesions < 10 mm in size, and at 1-2-year intervals for lesions 10-20 mm in size. For asymptomatic SELs > 20 mm in size that are not resected, ESGE suggests surveillance with EGD plus EUS at 6 months and then at 6-12-month intervals.Weak recommendation, very low quality evidence. 6: ESGE recommends endoscopic resection for type 1 gastric neuroendocrine neoplasms (g-NENs) if they grow larger than 10 mm. The choice of resection technique should depend on size, depth of invasion, and location in the stomach.Strong recommendation, low quality evidence. 7: ESGE suggests considering removal of histologically proven gastric GISTs smaller than 20 mm as an alternative to surveillance. The decision to resect should be discussed in a multidisciplinary meeting. The choice of technique should depend on size, location, and local expertise.Weak recommendation, very low quality evidence. 8: ESGE suggests that, to avoid unnecessary follow-up, endoscopic resection is an option for gastric SELs smaller than 20 mm and of unknown histology after failure of attempts to obtain diagnosis.Weak recommendation, very low quality evidence. 9: ESGE recommends basing the surveillance strategy on the type and completeness of resection. After curative resection of benign SELs no follow-up is advised, except for type 1 gastric NEN for which surveillance at 1-2 years is advised.Strong recommendation, low quality evidence. 10: For lower or upper GI NEN with a positive or indeterminate margin at resection, ESGE recommends repeating endoscopy at 3-6 months and another attempt at endoscopic resection in the case of residual disease.Strong recommendation, low quality evidence.
1: 欧洲消化内镜学会(ESGE)推荐内镜超声检查(EUS)作为描述上皮下病变(SEL)特征(大小、位置、起源层、回声性、形状)的最佳工具,但仅靠EUS无法区分所有类型的SEL。强烈推荐,中等质量证据。2: ESGE建议,对于所有具有提示胃肠道间质瘤(GIST)特征的SEL,如果其大小>20mm,或具有高风险特征,或需要手术切除或肿瘤治疗,均应进行组织学诊断。弱推荐,极低质量证据。3: ESGE推荐EUS引导下细针穿刺活检(EUS-FNB)或黏膜切开辅助活检(MIAB)用于大小≥20mm的SEL的组织学诊断。强烈推荐,中等质量证据。4: ESGE建议,对于诊断明确的无症状胃肠道平滑肌瘤、脂肪瘤、异位胰腺、颗粒细胞瘤、神经鞘瘤和血管球瘤,不进行监测。强烈推荐,中等质量证据。5: ESGE建议,对于未明确诊断的无症状食管和胃SEL,进行监测,3-6个月进行一次食管胃十二指肠镜检查(EGD),对于大小<10mm的病变,随后每2-3年进行一次;对于大小为10-20mm的病变,每1-2年进行一次。对于大小>20mm未切除的无症状SEL,ESGE建议6个月时进行EGD加EUS监测,随后每6-12个月进行一次。弱推荐,极低质量证据。6: ESGE推荐,对于1型胃神经内分泌肿瘤(g-NENs),如果其生长超过10mm,应进行内镜切除。切除技术的选择应取决于大小、浸润深度和在胃内的位置。强烈推荐,低质量证据。7: ESGE建议,考虑切除组织学证实的小于20mm的胃GIST作为监测的替代方案。是否切除的决定应在多学科会议上讨论。技术的选择应取决于大小、位置和当地专业知识。弱推荐,极低质量证据。